| Returns | 1W : 11.6% , 1M : 24.5%,1Y : 84.2% |
| Peers & Returns | 1W | 1M | 1Y |
| GLENMARK PHARMACEUTICALS | 11.6% | 24.5% | 84.2% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.8% | 10.2% | 40.1% |
| DR REDDYS LABORATORIES | 7.8% | 18.3% | 26.4% |
| DIVIS LABORATORIES | 1.7% | 12% | 63.2% |
| CIPLA | 7.2% | 22.8% | 58.3% |
| BIOCON | -1.4% | 3.4% | 14.3% |
| AUROBINDO PHARMA | 8.5% | 17.7% | 77.9% |
| LUPIN | 5.1% | 6.9% | 28.9% |
| TORRENT PHARMACEUTICALS | 1.5% | 7.8% | 15.5% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
20.64
P/E Calculated based on EPS of 27.5
[ Mar2020 - Consolidated Results ] 2.64
P/B Calculated based on Book Value of 214.65
[ Mar2020 - Consolidated Results ] 1.5
P/S Calculated based on Revenues of 10662.9 Cr
[ TTM - Consolidated Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-22% -49% -43% |
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 3.7% | 15.3% | 56.9% |
| S&P BSE MOMENTUM | 0.5% | 10.6% | 36% |
| S&P BSE MIDSMALLCAP | 0.2% | 1.7% | 80% |
| S&P BSE 150 MIDCAP | 0.1% | 1.4% | 78.1% |
| S&P BSE 400 MIDSMALLCAP | 0% | 1% | 81% |
| S&P BSE MID CAP | -0% | 0.7% | 68.4% |
| S&P BSE ALLCAP | -0.8% | -0.3% | 59.7% |
| S&P BSE 500 | -0.9% | -0.4% | 58.8% |
| S&P BSE 250 LARGEMIDCAP | -0.9% | -0.4% | 57.2% |
| S&P BSE 200 | -1% | -0.5% | 56.9% |
| S&P BSE LARGE MIDCAP | -1% | -0.7% | 55.6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MID SMALL400 | -0.1% | 0.9% | 80.8% |
| NIFTY MIDCAP150 | -0.3% | 0.9% | 76.5% |
| NIFTY FREE MIDCAP 100 | -0.4% | 1.3% | 77.9% |
| NIFTY MIDCAP 50 | -0.9% | -2.2% | 79.7% |
| NIFTY 500 | -0.9% | -0.4% | 58.3% |
| NIFTY LARGE MIDCAP 250 | -0.9% | -1.7% | 65% |
| NIFTY 200 | -1% | -0.4% | 55.9% |
